Page 161 - 南京医科大学自然版
P. 161

第45卷第6期         成永奇，陈乐延，郑明峰. ⅠA期肺腺癌预后高危影响因素及术后辅助治疗的研究进展［J］.
                  2025年6月                     南京医科大学学报（自然科学版），2025，45（6）：891-899                        ·899 ·


                    20978147                                           Oncol，2023，53（12）：1191-1200
               ［46］XIE S N，LIU Q Y，HAN Y Q，et al. Adjuvant chemothera⁃  ［51］FU R，HUANG J，TIAN X R，et al. Postoperative circula⁃
                    py can benefit the survival of stageⅠlung adenocarcino⁃  ting tumor DNA can refine risk stratification in resectable
                    ma patients with tumour spread through air spaces after  lung cancer：results from a multicenter study［J］. Mol
                    resection：propensity ⁃ score matched analysis［J］. Front  Oncol，2023，17（5）：825-838
                    Oncol，2022，12：905958                         ［52］JIANG Y，LIN Y C，FU W H，et al. The impact of adju⁃
               ［47］LV Y L，LI S W，LIU Z C，et al. Impact of surgery and  vant EGFR⁃TKIs and 14⁃gene molecular assay on stageⅠ
                    adjuvant chemotherapy on the survival of stage Ⅰ lung  non⁃small cell lung cancer with sensitive EGFR mutations
                    adenocarcinoma patients with tumor spread through air  ［J］. EClinicalMedicine，2023，64：102205
                    spaces［J］. Lung Cancer，2023，177：51-58        ［53］ XIA L，MEI J D，KANG R，et al. Perioperative ctDNA⁃
               ［48］ PIGNON J P，TRIBODET H，SCAGLIOTTI G V，et al.        based molecular residual disease detection for non⁃small
                     Lung adjuvant cisplatin evaluation：a pooled analysis by  cell lung cancer：a prospective multicenter cohort study
                     the LACE collaborative group［J］. J Clin Oncol，2008，26  （LUNGCA ⁃ 1）［J］. Clin Cancer Res，2022，28（15）：
                    （21）：3552-3559                                     3308-3317
               ［49］LIU C H，PENG Y J，WANG H H，et al. Heterogeneous  ［54］FORDE P M，SPICER J，LU S，et al. Neoadjuvant nivo⁃
                    prognosis and adjuvant chemotherapy in pathological  lumab plus chemotherapy in resectable lung cancer［J］.
                    stage Ⅰ non ⁃ small cell lung cancer patients［J］. Thorac  N Engl J Med，2022，386（21）：1973-1985
                    Cancer，2015，6（5）：620-628                     ［55］ GALE D，HEIDER K，RUIZ⁃VALDEPENAS A，et al.
               ［50］ ADACHI H，SAITO A，SHINTANI Y，et al. Is adjuvant     Residual ctDNA after treatment predicts early relapse in
                    chemotherapy for completely resected p⁃stageⅠA（>2 cm）  patients with early⁃stage non⁃small cell lung cancer［J］.
                    and stageⅠB non⁃small⁃cell lung cancer beneficial for  Ann Oncol，2022，33（5）：500-510
                    elderly patients? A large，retrospective cohort study                   ［收稿日期］ 2024-11-28
                    based on real ⁃ world data from Japan［J］. Jpn J Clin                        （本文编辑：蒋      莉）
                

               （上接第890页）                                         ［79］ LEE S H，CHO S Y，YOON Y，et al. Bifidobacterium
                    （6371）：91-97                                       bifidum strains synergize with immune checkpoint inhibi⁃
               ［73］ANDREWS M C，DUONG C P M，GOPALAKRISHNAN              tors to reduce tumour burden in mice［J］. Nat Microbiol，
                    V，et al. Gut microbiota signatures are associated with  2021，6（3）：277-288
                    toxicity to combined CTLA⁃4 and PD⁃1 blockade［J］. Nat  ［80］ WU Y H，WU J L，LIN Z K，et al. Administration of a
                    Med，2021，27（8）：1432-1441                           probiotic mixture ameliorates cisplatin⁃induced mucositis
               ［74］DAI Z J，ZHANG J Q，WU Q，et al. Intestinal microbiota：  and pica by regulating 5⁃HT in rats［J］. J Immunol Res，
                    a new force in cancer immunotherapy［J］. Cell Commun  2021，2021：9321196
                    Signal，2020，18（1）：90                         ［81］DE RUYSSCHER D，NIEDERMANN G，BURNET N G，
               ［75］ CHEN D F，WU J Y，JIN D C，et al. Fecal microbiota    et al. Radiotherapy toxicity［J］. Nat Rev Dis Primers，
                    transplantation in cancer management：current status and  2019，5（1）：13
                    perspectives［J］. Int J Cancer，2019，145（8）：2021-2031  ［82］ XIA C F，JIANG C L，LI W Y，et al. A phaseⅡrando⁃
               ［76］ZHANG F M，CUI B T，HE X X，et al. Microbiota trans⁃   mized clinical trial and mechanistic studies using im⁃
                    plantation：concept，methodology and strategy for its  proved probiotics to prevent oral mucositis induced by
                    modernization［J］. Protein Cell，2018，9（5）：462-473   concurrent radiotherapy and chemotherapy in nasopharyn⁃
               ［77］ ALEXANDER J L，WILSON I D，TEARE J，et al. Gut        geal carcinoma［J］. Front Immunol，2021，12：618150
                    microbiota modulation of chemotherapy efficacy and  ［83］ MITRA A，GROSSMAN BIEGERT G W，DELGADO A
                    toxicity［J］. Nat Rev Gastroenterol Hepatol，2017，14（6）：  Y，et al. Microbial diversity and composition is associated

                    356-365                                            with patient ⁃ reported toxicity during chemoradiation
               ［78］ IIDA N，DZUTSEV A，ANDREW STEWART C，et al.           therapy for cervical cancer［J］. Int J Radiat Oncol Biol
                     Commensal bacteria control cancer response to therapy  Phys，2020，107（1）：163-171
                     by modulating the tumor microenvironment［J］. Science，                 ［收稿日期］ 2025-03-07
                     2013，342（6161）：967-970                                                     （本文编辑：蒋      莉）
   156   157   158   159   160   161   162   163   164   165   166